You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 133 No. 11, November 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Paper
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Burns
 •Pediatric Surgery
 •Alert me on articles by topic

Ciprofloxacin as a Therapeutic Modality in Pediatric Burn Wound Infections

Efficacious or Contraindicated?

John P. Heggers, PhD; Cynthia Villarreal, RPh; Pat Edgar, RN, CIC; Steven Wolf, MD; Gordon L. Klein, MD; Susan D. John, MD; Manu Desai, MD; David N. Herndon, MD

Arch Surg. 1998;133:1247-1250.

Background  Food and Drug Administration regulations state that ciprofloxacin hydrochloride may cause arthropathies. For this reason, such therapy is contraindicated in the pediatric population. However, several studies in children with cystic fibrosis have found the drug to be efficacious. Our hypothesis was that ciprofloxacin treatment is justified in the case of multiresistant organisms in burn populations.

Design  During a 4-year period (January 1, 1993, to December 31, 1997) we treated 56 of our pediatric burn patients with ciprofloxacin when cultures proved resistant to other antibiotics. The burn area was 65% of the total body surface area. The average patient age was 8.4 years. Of the 56 patients who received ciprofloxacin, 50 received the recommended dose. Biopsy specimens were assessed for quantitative bacteriology and antibiotic sensitivity. Radiologic review was conducted to examine for arthropathy.

Results  All patients showed unequivocal reduction in quantitative bacterial counts, and susceptibility to ciprofloxacin remained stable without the development of resistance. Of the 56 patients treated, 42 had a major reduction in their quantitative wound biopsies from 106 to less than 100 colonies per gram of tissue, while the remaining 14 were observed to have a 2- to 3-log decrease. No arthropathy was detected in any of the 56 patients receiving ciprofloxacin. Review of the patients' charts showed no documented adverse events associated with the use of ciprofloxacin. All patients survived their thermal injury and the complications associated with it without any untoward problems or complications of arthropathy.

Conclusion  On the basis of these data, ciprofloxacin therapy in the treatment of immunosuppressed pediatric burn patients is efficacious and does not cause arthropathy.


From the Departments of Surgery (Drs Heggers, Wolf, Desai, and Herndon), Pharmacy (Ms Villarreal), Pediatrics (Drs Klein and John), and Radiology (Dr John), University of Texas Medical Branch, and Shriners Hospital for Children, Burns Hospital (Drs Heggers, Wolf, Klein, Desai, and Herndon, and Mss Villarreal and Edgar), Galveston.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Therapeutic Efficacy of "Nubiotics" against Burn Wound Infection by Pseudomonas aeruginosa
Dale et al.
Antimicrob. Agents Chemother. 2004;48:2918-2923.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.